This analysis identifies initiatives focused on the development of gut microbiome therapeutics. Disruption of the gut microbiome causes a range of health issues, including gastrointestinal diseases, immuno-oncological diseases, and metabolic diseases.
• Over the last decade, gut microbiome therapeutics have largely relied on untargeted approaches, such as fecal microbiome therapy (FMT), probiotics, prebiotics, and synbiotics.
• Emerging technologies in this space include targeted drugs, cultured commensals, bio-engineered commensals, and bacteriophage therapies. There has been an increase in investments and government funding for the development of gut microbiome therapeutics.
Sign up for a complimentary Growth Pipeline Dialog™
A Growth Pipeline Dialog is a structured open discussion with our growth experts providing unparalleled industry intelligence, technology advancements, and proven implementation best practices. This discussion will spark innovative thinking and help generate a pipeline of growth opportunities you can leverage to maximize your company’s future growth potential.
